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IL-10 production by CD19(+)CD5(+) B cells was investigated, by determining the 
expression levels of CD19, a classical B cell marker. Peripheral mononuclear cells 
were stained with fluorescence-conjugated anti-CD5, anti-CD19, anti-IL-10, and 
Annexin V. Interestingly, IL-10-producing B cells were found to be localised within 
the CD19(low)CD5(+) B cell subset. Apoptotic changes were also observed mainly 
in CD19(low) cells among B cells. Thus, CD5(+) B cells should be classified as 
CD19(high) and CD19(low) cells, and the immunological significance of CD19 for 
the IL-10 production by CD5(+) B cells requires further studies.
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CD5(+) B cells are a subset of B cells known as regulatory B cells,1 of and are 
shown to negatively regulate immune responses through the production of IL-10.2 
We previously described a relationship between IL-10-producing regulatory B 
cells and diseases such as human food allergies and atopic dermatitis.3 IL-10-pro-
ducing CD19(+)CD5(+) B cell has been suggested as Br1 like Tr1, IL-10-produc-
ing T helper cell, and Br1 is associated with tolerance of food allergy. A recent 
study found that IL-10-producing regulatory B cells are predominantly localised 
within a rare CD19(+)CD5(+)CD1d(high) B cell subset.4 CD19 is a B cell marker 
that positively regulates B cell responses by controlling intrinsic and stimulus-de-
pendent signalling thresholds.5 In this study, we further characterised CD5(+) B 
cells, based on CD19 expression levels, and found that CD19(low)CD5(+) B cells 
were the major subpopulation that produced IL-10.
PBMCs were obtained from venous blood of five normal subjects who had vis-
ited the Department of Allergy and Clinical Immunology at the Seoul Allergy 
Clinic between March and May 2010. Signed consent forms were obtained from Jae Ho Lee, et al.
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USA), and the data were analysed with CellQuest software 
(BD Biosciences). 
CD19 staining of PBMCs revealed two subpopulations of 
CD19(+) B cells, CD19(high) and CD19(low). Histogram of 
CD19 expression clearly, showed two peaks of CD19(+) 
cells (Fig. 1A). CD5 staining was used to further characterise 
these cells. CD19(high) and CD19(low) B cells were clearly 
separated by resolving with the expression of CD19 and 
CD5 (Fig. 1B), with SSC and CD19 expression (Fig. 1C) 
and with FSC and CD19 expression (Fig. 1D). Furthermore, 
apoptosis frequencies were 4.33% in CD19(-) non-B cell, 
4.33% in CD19(high) B cells, and 16.95% in CD19(low) B 
cells (Fig. 2). 
Among the CD5(-) cells, 22.68% were CD19(+) and 
10.01% were CD19(high), whereas, 12.09% were CD19(+) 
and 3.59% were CD19(high) among the CD5(+) cells (Fig. 
3A). Both CD5(+) and CD5(-) B cells showed CD19(high) 
and CD19(low) B cell subpopulations. According to the ex-
pression of CD5, CD19(low) cells showed both CD19(low) 
CD5(+) B cells and CD19(low)CD5(-) B cells (Fig. 3B). 
Based on these data, CD19(+) B cells were classified into 
four groups (Fig. 3C).
As shown in a representative plotting (Fig. 4), predomi-
nant production of IL-10 was observed from a CD19(low)
CD5(+) B cell population. IL-10 was produced predomi-
nantly from CD19(low)CD5(+) cells among B cells (Fig. 
5A). The frequencies of IL-10-producing cells were as fol-
either patients or parents. The study was approved by the 
Institutional Review Board of Chungnam University Hos-
pital, Daejeon, Korea.
PBMCs were isolated from venous blood using density 
gradient separation and Ficoll-Hypaque (Biomedicals, Au-
rora, OH, USA). PBMCs were resuspended at 1×106 cells/
mL in α-minimum essential medium (α-MEM; Irvine Sci-
entific, Santa Ana, CA, USA) and stained with specific 
monoclonal antibodies, including allophycocyanin (APC)-
labelled anti-CD19 (eBioscience, San Diego, CA, USA), 
phycoerythrin (PE)-Cy7-labelled anti-CD5, (eBioscience) 
and fluorescein (FITC)-labelled Annexin V (eBioscience). 
Cells were prepared at a concentration of 1×106 cells were 
suspended in 100 μL of FACS staining buffer (eBioscience, 
San Diego, CA, USA) in eppendorf tubes. Monoclonal an-
tibodies for surface staining were added at a concentration of 
1 μg/mL according to the manufacturer’s instructions. The 
cells were incubated for 1 hour in the dark and washed 
three times with FACS staining buffer. The cells were then 
resuspended in 500 μL of FACS staining buffer prior to 
flow cytometric analysis. 
Following staining for CD5, CD19, and Annexin V, the 
cells were fixed and permeabilised using a fixation/permea-
bilisation kit (eBioscience). After fixation/permeabilisation, 
the cells were stained with a PE-labelled anti-IL-10 mono-
clonal antibody (eBioscience). The stained cells were ac-
quired on a FACSCaliber (BD Biosciences, Milpitas, CA, 
Fig. 1. CD19(high) and CD19(low) subpopulations of B cells. Fresh PBMCs 
from normal human subjects were stained for CD19 and CD5. (A) Histogram 
of CD19 expression in CD5(-) cells and CD5(+) B cells, (B) CD19(high) and 
CD19(low) B cells by CD5 and CD19 expression, (C) CD19(high) and CD19(low) 
B cells by SSC, (D) CD19(high) and CD19(low) B cells by FSC. CD19H, CD19 
(high) B cells; CD19L, CD19(low) B cells.
Fig. 2. Apoptosis of CD19(high) and CD19(low) B cells. CD19, APC-conjugated 
CD19; Annexin V, FITC-conjugated Annexin V. APC, allophycocyanin.
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nantly expressed by the CD19(low)CD5(+) B cell subpopu-
lation, previous reports have shown that intracellular IL-10 
expression by B cells is diminished in CD19-deficient mice.7 
In this study, IL-10 was found to be mainly produced by 
CD19(low)CD5(+) B cells however, CD19 also seemed to 
be necessary for IL-10 production by CD5(+) B cells. 
B cells do not express IL-10 if not activated in vitro.8,9 In 
our recent study, IL-10 producing regulatory B cells prolifer-
ated in response to food allergens in the tolerant subjects.10 
Humans are challenged continuously by tolerized antigens, 
including food antigens, and the present study showed that 
IL-10-producing regulatory B cells seem to be present in 
normal subjects.
lows: 15.2±3.4% in CD19(low)CD5(+) B cells; 0.5±0.2% 
in CD19(high)CD5(+) B cells; 2.3±0.7% in CD19(low)
CD5(-) B cells; and 1.1±0.4% in CD19(high)CD5(-) B cells 
(Fig. 5B). Interestingly, most of the IL-10-producing CD19 
(low)CD5(+) B cells were apoptotic. The frequencies of 
apoptotic IL-10-producing cells were as follows: 11.2±3.0% 
in CD19(low)CD5(+) B cells; 0.5±0.1% in CD19(high)
CD5(+) B cells; 1.9±0.5% in CD19(low)CD5(-) B cells; 
and 0.7±0.2% in CD19(high)CD5(-) B cells. The frequen-
cies of non-apoptotic IL-10-producing cells were as follows: 
4.0±0.4% in CD19(low)CD5(+) B cells; 0.1±0.1% in CD19 
(high)CD5(+) B cells; 0.4±0.2% in CD19(low)CD5(-) B 
cells; and 0.4±0.2% in CD19(high)CD5(-) B cells.
B cells are classically divided into CD5(+) B1 cells and 
CD5(-) B2 cells. In this study, we further subdivided these 
two groups of cells on the basis of CD19 expression level 
(Fig. 1) and found that IL-10 was mainly produced by the 
CD19(low)CD5(+) B cell subpopulation (Figs. 4 and 5). 
CD19 is a member of the immunoglobulin superfamily and 
is expressed only on B cells and follicular dendritic cells.6 
CD19 is generally considered to be a positive regulator of 
both intrinsic and stimulus-dependent signalling thresholds 
in B cells.5 Although we found that IL-10 was predomi-
Fig. 3. Demarcation of B cell subpopulations according to the expression of 
CD5 and CD19. (A) Resolving CD19(high) and CD19(low) cells by the expres-
sion of CD5, (B) Zebra plotting of CD19(high) and CD19(low) cells by the ex-
pression of CD19 and CD5, (C) Demarcation of B cell subpopulations accord-
ing to the expression of CD5 and CD19. *1 arrow, CD19(low)CD5(-) B cells; *2 
arrow CD19(low)CD5(+) B cells; CD5(-), CD5(-) cells; CD5(+), CD5(+) cells; 
CD19(high), CD19(high) B cells; CD19(low), CD19(low) B cells.
Fig. 5. IL-10 production from CD19(low)CD5(+) B cells among B cells. (A) 
Resolving CD19(high) and CD19(low) cells by the expression of CD19 and 
IL-10 (upper box, zebra plotting; lower box, density plotting of CD19(+) B 
cells for IL-10 production, (B) IL-10-producing cell frequency (%) in B cell 
populations divided on the basis of CD19 and CD5 expression. *1 arrow, IL-
10-producing CD19(low) B cells; *2 and *3 arrow, non-IL-10-producign 
CD19(high) and CD19(low). B cells; IL-10(+) total, total IL-10-producing B 
cells; Annexin V(+)/IL-10(+), IL-10-producing B cells undergoing apoptosis; 
Annexin V(-)/IL-10(+), IL-10-producing B cells without apoptosis.
Fig. 4. Representative IL-10 production and apoptosis profiles of B cell popu-
lations subdivided by CD19 and CD5 expression (A). (B) CD19(high)CD5(-) B 
cells (section a); (C) CD19(high)CD5(+) B cells (section b); (D) CD19(+)CD5(-) 
B cells; (E) CD19(low)CD5(-) B cells (section c); (F) CD19(low)CD5(+) B cells 
(section d). The percentage of each population is indicated in the plotting 
box. X-axis, PE-conjugated IL-10 expression; Y-axis, FITC-conjugated 
Annexin V; Arrow, IL-10-producing CD19(+) B cells.
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cal role of CD19 in IL-10 production by CD5(+) B cell and 
the functional differences of B cell subsets expressing differ-
ent levels of CD19 require further investigation.
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